Indication
Ocular melanoma
11 clinical trials
16 products
6 drugs
Product
AU-011Clinical trial
A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal MelanomaStatus: Completed, Estimated PCD: 2021-01-26
Product
Light-activated AU-011Clinical trial
Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients With Melanoma or Non-Small Cell Lung Cancer (NSCLC) Brain Metastases (BM)Status: Completed, Estimated PCD: 2020-11-19
Product
PembrolizumabClinical trial
Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV MelanomaStatus: Completed, Estimated PCD: 2023-01-26
Product
IpilimumabProduct
NivolumabProduct
RelatlimabClinical trial
A Proof of Concept Study of TBio-4101 (an Autologous Selected and Expanded Tumor Infiltrating Lymphocyte [TIL] Therapy) Using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients With Relapsed or Refractory Melanoma (Phase 1)Status: Recruiting, Estimated PCD: 2024-08-31
Drug
TBio-4101Drug
cyclophosphamideProduct
FludarabineDrug
IL-2Clinical trial
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal MelanomaStatus: Recruiting, Estimated PCD: 2025-06-01
Product
AfliberceptProduct
FalseClinical trial
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaStatus: Recruiting, Estimated PCD: 2026-03-01
Product
BelzupacapProduct
Sham TreatmentClinical trial
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
6MHPProduct
NeoAg-mBRAFProduct
PolyICLCDrug
CDX-1140Clinical trial
A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaStatus: Recruiting, Estimated PCD: 2024-12-09
Product
OlaparibClinical trial
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Product
DarovasertibClinical trial
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Drug
T-VECDrug
Lurbinectedin